S2612 The MASH Educational Alliance Program Led to Significant Knowledge Improvement Among Front-Line Providers in the United States

Introduction: MASH is the most prevalent chronic liver disease, contributing to mortality, morbidity, and economic burden. However, despite the substantial impact of this disease, the emergence of new biomarkers, promising treatment options, and understanding of new treatment options for MASH among providers remain limited. We aimed to assess the impact of targeted education for providers in the U.S. Methods: CLDF, GNC, and GHAPP members developed the MASH Educational Alliance Program (MEAP). Specifically, the content for the MEAP was created by faculty and underwent continuing medical education (CME) accreditation. From April 2024 to March 2025, a national live CME education initiative focusing on screening, diagnosing, and managing MASH was conducted for gastroenterologists and advanced practice providers (APPs). The initiative comprised 290 national live events. The course assessed outcomes at Moore’s Levels 1 (Participation) and 2 (Satisfaction). CE Outcomes and MASH Alliance collaborated on an outcomes study based on key performance measurements within the various initiatives to assess the attendees’ Levels 3 and 4 (Knowledge and Competence). A sample of learners completed a 30-day follow-up assessment, and the results were compared to those of a demographically matched control group who did not engage in the activities to understand lasting educational effects and how they apply the information in their practices (Level 5 – Performance). Results: A total of 5,322 learners participated. The following reflects significant knowledge and competence improvements analyzed by comparing a sample of learners to a non-learner control group. Learners post-education were more likely to recognize the global prevalence of MASLD at 38% (P < 0.001) and identify FIB-4 as the most recommended non-invasive test than pre-test scores (P < 0.001). Learners were likelier to appropriately diagnose a simulated patient with MASH/MASLD (P = 0.027) and to initiate treatment in a patient with MASH (P = 0.009). Ninety-eight percent of learners reported that MEAP has helped them address key barriers in their practice. Learners were more familiar with clinical trials managing patients with NASH/MASH, specifically the MAESTRO-NASH and ESSENCE trials. Conclusion: A multifaceted and targeted educational program (MEAP) significantly improved gastroenterologists' and APPs' knowledge of MASH in clinical practice.